semaglutide and prolactinoma - Oncology Prolactinoma: Video, Causes, and Symptoms

As previously described, the individual hospital payment parameters are taken from the best available data, including the December 2022 update of the FY 2022 MedPAR file, the December 2022 update to the PSF, and the most recent available cost report data from the December 2022 update of the FY 2021 HCRIS

The FDA declared the tirzepatide shortage resolved in October 2024, which closed the main legal pathway for large-scale compounding

Participants were evaluated at 3-month intervals for up to 12 months

Patient education should emphasize the limited evidence base, experimental nature of treatment, and importance of ongoing monitoring

All injectable dosing protocols are extrapolations from the oral trial, animal data, and clinical practice experience